These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36239850)

  • 1. Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.
    Uzoigwe C; Noone J; Liang Y; Ali SN; Gamble C
    Diabetes Ther; 2022 Dec; 13(11-12):1861-1874. PubMed ID: 36239850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
    King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
    Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
    Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
    Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
    Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
    Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in Diabetes-Related Hospitalizations and Medical Costs After Dexcom G6 Continuous Glucose Monitor Initiation in People with Type 2 Diabetes Using Intensive Insulin Therapy.
    Hannah KL; Nemlekar PM; Green CR; Norman GJ
    Adv Ther; 2024 Jun; 41(6):2299-2306. PubMed ID: 38619722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
    Hoog M; Paczkowski R; Huang A; Halpern R; Buysman E; Stackland S; Zhang Y; Wangia-Dixon R
    Diabetes Ther; 2023 Nov; 14(11):1947-1958. PubMed ID: 37740872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses.
    Mehta D; Davis M; Epstein AJ; Wensel B; Grinnell T; Williams GR
    Neurol Ther; 2020 Dec; 9(2):585-598. PubMed ID: 32949379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
    Foster SA; Hoyt M; Ye W; Mason O; Ford JH
    Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
    Dalal MR; Kazemi M; Ye F; Xie L
    Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin.
    Blonde L; Raccah D; Lew E; Meyers J; Nikonova E; Ajmera M; Davis KL; Bertolini M; Guerci B
    Diabetes Ther; 2018 Jun; 9(3):1169-1184. PubMed ID: 29675797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource utilization and costs 2 years pre- and post-lumbar spine surgery for stenosis: a national claims cohort study of 22,182 cases.
    Koltsov JCB; Sambare TD; Alamin TF; Wood KB; Cheng I; Hu SS
    Spine J; 2022 Jun; 22(6):965-974. PubMed ID: 35123048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
    McAllister P; Lamerato L; Krasenbaum LJ; Cohen JM; Tangirala K; Thompson S; Driessen M; Casciano J; Dotiwala Z; Mauskop A
    J Headache Pain; 2021 Dec; 22(1):156. PubMed ID: 34930112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
    Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
    J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.